Wang Shuxin entered into the Equity Transfer Agreement to acquire 30.2653% stake in Tianjin Alpha Healthcare Products Co., Ltd. from Tianjin TEDA Biomedical Engineering Company Limited for CNY 10.86 million.

Wang Shuxin entered into the Equity Transfer Agreement to acquire 30.2653% stake in Tianjin Alpha Healthcare Products Co., Ltd. from Tianjin TEDA Biomedical Engineering Company Limited (SEHK:8189) for CNY 10.86 million on December 28, 2021. Upon the completion, Tianjin TEDA Biomedical Engineering company will no longer hold any equity interest in Tianjin Alpha. The consideration shall be paid by instalments over an overall payment period of 18 months, of which 50% of the total consideration will be paid in aggregate in the first 12 months, payable in 12 equal monthly instalments, i.e. CNY 0.4525 million per month, and the remaining total consideration will be paid in equal monthly instalments in the last 6 months, i.e. CNY 0.905 million per month.

The relevant parties have signed the Equity Pledge Agreement 1 and the Equity Pledge Agreement 2, In order to ensure the timely performance of the Equity Transfer Agreement. As on January 3, 2022, The parties has signed pledge agreements. Tianjin Alpha Healthcare Products reported a loss of CNY 1.934074 million for the year ended December 31, 2020.